Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea Pharmaceutica has released new data on the antibacterial compounds BAL30072 and ceftobiprole as well as the antifungal drug isavuconazole at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Vienna.
Subscribe to our email newsletter
BAL30072 is a new siderophore sulfactam antibiotic. The penicillin-binding-protein inhibition and its bactericidal mode of action confer potent in-vitro and in-vivo activity against Gram-negative bacteria.
Pathogens such as Pseudomonas spp. and Acinetobacter spp. as well as the enterobacteria Escherichia coli and Klebsiella pneumoniae are increasingly multi-resistant and difficult-to-treat Gram-negative ‘superbugs’. BAL30072 overcomes most mechanisms of resistance to currently marketed beta-lactam antibiotics found in these bacilli.
New research data presented at ECCMID by Miriagou and co-authors showed that BAL30072 demonstrates in-vivo efficacy against clinical metallo-beta-lactamase producing isolates of E coli and K pneumoniae, resistant to several antibiotics (poster P 1240).
Furthermore, data from Carmeli and co-authors showing BAL30072’s strong in-vitro and in-vivo activity against extended-spectrum-beta-lactamase producing E. coli was selected for an oral presentation at ECCMID’s ‘New antibacterial agents’ session (O 376).
Basilea Pharmaceutica said that BAL30072 has previously been shown to have potent antibacterial activity in-vitro against multi-resistant Gram-negative bacteria, including carbapenem-resistant strains. New in-vivo data demonstrate that co-administration with meropenem enhances BAL30072’s activity against resistant Gram-negative bacteria (E coli, K pneumoniae), including strains that are not susceptible to BAL30072 and meropenem as single agent, respectively (P 1240).
Basilea expects to initiate a phase I clinical development program for the investigation of BAL30072 in humans in the second half of 2010.